Genentech on X: "#Breaking: The @US_FDA granted priority review to our treatment for primary membranous nephropathy (pMN), a chronic, idiopathic kidney condition. If approved, it would be the first FDA-approved therapy specifically indicated to treat this disease. Read more: https://t.co/xj3QJELzN9"

Genentech

@genentech

#Breaking: The @US_FDA granted priority review to our treatment for primary membranous nephropathy (pMN), a chronic, idiopathic kidney condition. If approved, it would be the first FDA-approved therapy specifically indicated to treat this disease. Read more: gene.com/media/press-re…

00:00

5:02 AM · Jul 15, 20262.6KViews

4

10